Polypeptide With Localisation/Targeting Motif TRIZ Cases

Higher-affinity mesothelin binding helps CAR therapy target solid tumor cells more effectively despite fibrous tissue barriers.

Fusion proteins pair DNA-binding domains with deaminases to correct LHON mitochondrial mutations at 3460, 11778, and 14484.

Optimized signal sequences drive CRM197 into the E. coli periplasm, improving secretion and purity while limiting host-cell toxicity.

ASGPR-targeted antigen conjugates drive liver uptake to induce immune tolerance and clear antibodies linked to rejection, autoimmunity, and allergy.

A domain-based fusion polypeptide binds DNA, RNA, proteins, or polysaccharides non-covalently for efficient cell entry across diverse cell types.

A synthetic nucleoprotein complex pairs a short DNA-binding domain with a targeting nucleic acid to enable compact, less immunogenic genome editing.

Membrane-anchored IL-7 helps modified TILs resist tumor microenvironment inhibition, boosting proliferation, persistence, and cytotoxicity.

A dual-target CAR-T converts PD-L1 inhibition into activation while co-targeting VEGFR1 or HER2 to improve solid tumor killing with lower off-tumor toxicity.

By combining a CD33-binding scFv with CD3 zeta and 4-1BB signaling, engineered immune cells target AML cells and support sustained anti-leukemia activity.

GSK-3beta inhibition with cytokines and flow sorting yields T memory stem cells with stronger self-renewal and persistence for adoptive therapy.

Specific 5′ and 3′ UTR selection boosts mRNA expression in endothelial cells and helps restore anti-permeability and anti-inflammatory functions.

A fully human anti-CD19 scFv replaces heterologous antibodies in CAR-T cells to lower immunogenicity and support longer in-body survival.

TRBC1-specific binding domains target malignant T-cells while sparing TRBC2-positive healthy cells to reduce immunosuppression in therapy.

Functionalized 3D microcarriers mimic lymph-node niches to expand potent T cells at high density with lower cytokine demand.

Intracellular erLSP-IL-15 gives NK-92 cells cytokine-independent growth while limiting harmful IL-15 secretion and preserving cytotoxicity.

Cytokine activation and lentiviral transduction improve primary NK cell gene transfer and long-term expression for scalable immunotherapy.

Conditional CARs and multispecific EpCAM binders improve tumor cell targeting while helping balance therapeutic efficacy and side effects.

A three-step anion exchange, hydrophobic interaction, and hydroxyapatite process removes DNA and proteins to purify soluble PSGL-1 at scale.

By coupling PD-1 tumor binding with 4-1BB signaling, these fusion proteins boost T cell survival, proliferation, and tumor killing.

Engineered AChR CAAR T cells selectively kill autoantibody-producing B cells to treat myasthenia gravis while limiting broad immunosuppressive side effects.

Ligand-driven FKBP-FRB dimerization selectively expands engineered cells while limiting proliferation in non-bound cell populations.

By coupling heterologous antigens to herpesvirus gD, these constructs disrupt HVEM-BTLA signaling and boost CD8+ T cell responses.

Lectin-based CAR-T cells target abnormal tumor glycans to improve epithelial cancer recognition and boost cytotoxicity and interferon-gamma production.

Engineered Listeria delivers IL-2, IL-12, or CD40L into tumors to boost T-cell activity while limiting systemic cytokine toxicity.

Exogenous CD8α/CD8β helps low-affinity NeoTCR T cells stabilize TCR-pMHC binding and boost tumor killing, proliferation, and infiltration.

Targeted MHC I editing and chimeric receptor engineering improve immune cell persistence and tumor killing while reducing fratricide and graft risks.

By combining HLA-G CAR targeting with a PD-L1/CD3 bispecific engager, this case improves solid tumor cell killing and tumor growth inhibition.

Self-assembled hyaluronic acid nanoparticles retain therapeutic peptide in ocular tissue to inhibit angiogenesis with fewer injections and side effects.

Cascade fusion proteins and crRNA enable precise Type I-E CRISPR activation in eukaryotic cells while preserving targeting specificity.

Epigenetic editors repress TRAC without permanent DNA cutting, reducing translocation and off-target mutation risks in engineered cells.

Bispecific CD3-SSTR2 engagement and engineered CAR-T cells address weak NET immunotherapy by boosting targeted T-cell killing.

C-terminal tail truncation in retroviral envelope glycoproteins boosts SLC1A5-targeted human cell entry and supports higher vector titers.

A peptide-tagged lysosomal enzyme fusion protein improves lysosome uptake while reducing off-target receptor binding and furin cleavage.

Lid-region amino acid substitutions in Cas12a improve DNA editing efficiency while reducing indiscriminate single-strand DNA degradation.

A muscle-targeting rAAV enables sustained insulin-albumin expression in dogs and cats, reducing repeat injections and vet visits.

Structured CPP conjugates improve antisense oligonucleotide delivery by boosting exon skipping and dystrophin restoration while reducing toxicity.

CARs that bind TRAILshort help immune cells selectively kill TRAILshort-positive cancer cells while reducing toxicity to healthy cells.

Functionalized polymers combine inflammasome activators and TLR agonists to boost T-cell responses and improve neoantigen vaccine efficacy.

Engineered dual-guide CRISPR-Cas improves transgene integration and expression in eukaryotic cells while preserving post-transfection viability.

A CD38/CD3 bispecific engager recruits T cells to kill CD38-high myeloma cells while limiting damage to CD38-low immune cells.

Amino acid deficiency triggers reversible transgene expression in T and NK cells, helping balance anti-tumor activity with lower toxicity.

An oncolytic virus expressing tumor antigens helps CAR-immune cells penetrate solid tumors and improve targeted tumor killing.

BCMA-directed CAR-T cells overcome CD19 limits in multiple myeloma by specifically recognizing and destroying malignant plasma cells.

Targets KRAS G12V presented by HLA-DR to destroy cancer cells while sparing normal cells, expanding immunotherapy options.

Separate CD28 and 4-1BB receptor constructs avoid steric interference and preserve T-cell cytotoxicity, proliferation, and IL-2 release.

A humanized BCMA CAR-T design with 4-1BB lowers inflammatory cytokines and CRS risk while sustaining multiple myeloma control.

A GLP-1 and glucagon fusion protein resolves the tradeoff between glucose control and stronger weight reduction by increasing calorie consumption.

Exogenous TdT in engineered non-human animals boosts V(D)J recombination diversity, improving therapeutic antibody and TCR production.

SUV39H1 inactivation helps CAR or TCR immune cells retain central memory traits, reduce exhaustion, and persist longer against tumors.

Reducing Mdh activity and boosting the Tat pathway improves heterologous protein secretion in coryneform bacteria and eases purification.